| INTRODUC TI ON
Human cytomegalovirus (HCMV) infection is a risk factor for renal allograft loss in patients with acute rejection. [1] [2] [3] The risk is greater for HCMV serostatus donor positive (D+) patients compared to donor negative (D-) patients, but the impact of recipient serostatus is unclear, with some studies showing poorest graft survival in the D+/ R+ group, but others showing worse outcomes in the D+/R-group.
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Antiviral prophylaxis against HCMV is associated with improved late graft function and survival. [5] [6] [7] [8] The mechanisms underlying these associations are unknown and could include direct viral cytolysis or antiviral immune-mediated allograft injury in association with acute rejection.
The immune response to HCMV and murine CMV (MCMV) has been well characterized (reviewed by Crough and Khanna 9 ). Initial control of primary CMV infection is mediated by natural killer (NK)
cells. [10] [11] [12] Among transplant patients, NK cells increase in number and activation status during episodes of HCMV viremia, and NK cells with activating receptors are enriched in peripheral blood during CMV infection. [13] [14] [15] [16] [17] Patients with NK activating killer cell immunoglobulin-like receptor (KIR) genotypes have lower rates of posttransplant HCMV infection. 15, 17, 18 Memory NK cells against MCMV infection preferentially reexpand upon viral rechallenge, and NK memory is also established after HCMV infection. [19] [20] [21] [22] NK cells assist in shaping the antiviral CD8+ T cell response. 9, [23] [24] [25] The CD8+ T cells control acute and persistent CMV infection (reviewed by Crough and Khanna
9
). In D+/R-transplantation, primary CMV infection induces the development of virus-specific CD8+ T cells with a differentiated phenotype, which are associated with protection from CMV disease. 26, 27 Among D+/R+ patients, CMV-specific T cells may expand posttransplant even in the absence of detectable CMV viremia. 28 Both HCMV and MCMV infection induce memory inflation, characterized by expansion of a CMV-specific population with an effector memory phenotype (T EM ) that differs from the contraction of noninflated memory T cells that maintain a central memory (T CM ) phenotype. [29] [30] [31] [32] [33] In human populations, HCMV-specific T cells constitute 5%-10% of the circulating memory repertoire.
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Although NK and CD8+ T cells control CMV disease, their impact upon renal allograft injury in CMV immune (R+) patients is not defined. In a murine allogeneic renal transplant model, MCMV D+/Rtransplants had increased intragraft CD45+ infiltrates compared to D-/R-transplants, including NK cells and CD4+ and CD8+ T cells.
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MCMV-infected allografts with acute rejection demonstrated more severe late fibrosis compared to MCMV-uninfected grafts, suggesting that MCMV-associated early graft injury combined with acute rejection might contribute to late graft fibrosis. 36 NK depletion ameliorated MCMV-associated allograft damage, suggesting that virus-directed NK cells mediate allograft injury. 36 In this study, we investigated the impact of antiviral memory NK and CD8+ T cells upon MCMV-associated allograft injury by varying the recipient's infecting virus dose to generate differential memory CD8+ T cell responses (T CM vs T EM ), or by infecting the recipient with a different MCMV strain from the donor organ.
| MATERIAL S AND ME THODS

| Virus and animals
MCMV Smith strains, either wild-type (MCMV-WT) or with a deletion mutation of the m157 open reading frame (MCMVΔm157, kind gift of S. Jonjic, University of Rijeka, Rijeka, Croatia) were propagated and stored as previously described. 35 BALB/cJ or C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed as described in Supplemental Methods. Murine experimental protocols were approved by the Institutional Animal Care and Use Committees.
| Renal transplantation surgery
Donor BALB/cJ ("BALB," H-2 d ) mice were infected by intraperitoneal injection with MCMVΔm157 at 10 4 plaque-forming units (pfu) for all D+ transplants. Recipient C57BL/6J ("B6," H-2 b ) mice were infected (R+) with MCMVΔm157 at either 10 2 pfu (low-dose) or 10 4 pfu (high-dose), or with MCMV-WT at 10 4 pfu. Thus, all D+ donor kidneys had the same virus strain and dose, whereas recipient infection conditions differed for each experimental group. All mice were infected > 12 weeks prior to transplant to establish antiviral NK and CD8+ T cell memory. 31, 37, 38 Uninfected mice were used for D-/Rtransplants. Kidney transplantation was performed as described, retaining the contralateral native kidney for this non-life-sustaining transplant model. 35, 39 Recipients were treated with cyclosporine (Novartis Pharmaceuticals Corp., East Hanover, NJ) at 10 mg/kg/ day, subcutaneously once daily starting immediately postoperatively until terminal sacrifice at day 14 posttransplant. 40 Results from 6-8 animals were analyzed per experimental group. In addition, some infected BALB and B6 mice were sacrificed > 12 weeks after infection ("pretransplant" groups, n = 3-4/group) to establish baseline viral and immune parameters for comparison with transplant animals.
| Flow cytometry
Organs were processed for flow cytometry as described in 
| Histology and scoring
Allograft tissues were fixed for > 24 hours in 10% neutral buffered formalin (Sigma-Aldrich, St. Louis, MO), processed for paraffin embedding and sectioning, and stained with hematoxylin and eosin.
Sections were evaluated by a veterinary pathologist (T.R.S.) blinded to sample identity using a previously published 8-criteria scale with a maximum damage score of 24.
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| Cytokine bead immunoassay
Allografts, livers, and spleens were processed for cytokine detection using the LEGENDplex Mouse Inflammation Panel (Biolegend, San Diego, CA) as described in Supplemental Methods. Cytokine results were analyzed using LEGENDplex Data Analysis Software, Version 7.0 (VigeneTech Inc., Carlisle, MA) and depicted as picograms/gram tissue.
| IL-6 in vivo depletion
To deplete IL-6 in vivo, kidney transplant recipients were treated with neutralizing rat anti-mouse IL-6 antibodies (clone MP5-20F3)
or isotype matched control rat anti-mouse IgG1 antibodies (clone HRPN) (BioXCell, West Lebanon, NH) by intraperitoneal injection, starting on day 0 immediately posttransplant and subsequently every second day until terminal sacrifice ( Figure 6 ). Antibodies were dosed at 400 μg/dose × 2 doses, followed by 300 μg/ dose. 42, 43 Allografts were procured at day 14 posttransplant for histology and quantitation of IL-6, IL-17A, and IL-17A-producing CD4+ T cells.
| Quantitative DNA PCR for MCMV viral load
Quantitative DNA polymerase chain reaction (PCR) for MCMV viral loads in organs was performed as previously described, using primers and probes for MCMV immediate-early 1 (IE1) exon 4. 
| Statistical analysis
All experiments were analyzed using 6-8 animals for each experimental group, except for the IL-6 depletion experiment (n = 3/group).
Comparisons between 2 groups were analyzed using the Student's t test, and comparisons between 3 or more groups were analyzed by ANOVA using Prism 7.0 software, accepting statistically significant differences at a P value of < .05 (GraphPad, San Diego, CA). Results were depicted as means ± standard deviations (SD).
| RE SULTS
| Recipient immunity influences allograft NK cell infiltrates but not viral loads
MCMV D+/R-allografts have more severe allograft injury compared to D-/R-grafts, 35 but recipient immunity could either exacerbate immune-mediated allograft injury or prevent allograft injury by limiting viral replication. To determine whether prior recipient immunity is beneficial or detrimental, D+/R+ transplants (D/R MCMVΔm157, Intragraft NK infiltrates did not correlate with viral loads (d.n.s.).
| MCMV infection induces intragraft CD8+ T cell infiltrates that are not exacerbated by recipient immunity
BALB pretransplant D-and D+ kidneys ( Figure 1G ) had very few IFN-γ+ CD8+ T cell infiltrates. D-/R-allografts had significantly greater IFN-γ+ CD8+ T cell infiltrates than pretransplant donor kidneys (P = .0178), consistent with an alloimmune response ( Figure 1H ).
D+/R-allografts had significantly greater IFN-γ+ CD8+ T cell infiltrates compared to D-/R-grafts (P = .0439) and were similar to D+/ R+ grafts ( Figure 1H ). This result indicates that MCMV D+ infection induces greater CD8+ T cell infiltrates compared to D-grafts but are not influenced by prior recipient immunity (R+).
| MCMV donor and recipient infections are associated with allograft damage
Using an 8-criteria scale to quantitate allograft damage ( Figure 1I ), at day 14 posttransplant D-/R-allografts had lower damage scores (7.6 ± 1.6) compared to D+/R-grafts (10.57 ± 2.1, P = .027), consistent with prior studies. 36 D+/R+ transplant had higher damage scores (11.9 ± 1.4) than D-/R-grafts (P = .0022) but were similar to D+/Rgrafts. This result indicates that MCMV-infected (D+) allografts had greater histologic injury compared to uninfected grafts, regardless of recipient (R+ or R-) immune status. 
| Systemic NK and CD8+ T cell responses in MCMV recipient immune transplants
| Memory NK responses to MCMV-infected allografts vary by primary recipient virus dose
Next, memory NK responses were examined in allografts and spleens from D+/R+ recipients with either low-dose (10 Figure 4D ). However, no differences were observed for splenic GzB+ NK cells ( Figure 4E ), indicating that allograft-infiltrating cytotoxic NK responses ( Figure 4B) were not reflected systemically.
| MCMV infection induces intragraft
Th17 responses
Next, CD4+ T cell responses were evaluated in allografts and Figure 5A ). D+/R+ low-dose (10 2 ) recipients had the highest Th17 infiltrates, compared to both D+/R-(P = .0191) and D+/ R+ high-dose allografts (P = .0056).
The cytokine profile was compared between allografts from D+/ R+ low-dose (10 2 ) recipients and D+/R+ high-dose (10 4 ) recipients using a bead immunoassay ( Figure 5B ). Both Th17-inducing cytokines (IL-1β, IL-6, IL-23) and Th17-secreted cytokines (IL-17A, GM-CSF, TNF-α) were more abundant in grafts from low-dose recipients (light bars) compared to high-dose recipients (dark bars). Th17 cell infiltrates correlated with IL-17A cytokine quantity (R 2 = .5384, P = .0157) ( Figure 5C ). Liver and spleen IL-17A cytokine levels ( Figure 5F ) trended higher among D+/R+ low-dose recipients compared to highdose recipients but were not statistically significant, indicating that intragraft Th17 differences were not manifested systemically.
| IL-6 depletion ameliorates tubular degeneration
As intragraft Th17 cells were most abundant among D+/R+ lowdose (10 2 ) recipients, the effect of Th17 cell depletion was tested CD4+ cells ( Figure 6C ) were lower than isotype-treated recipients.
Allograft histology showed decreased tubular degeneration in IL-6
depleted recipients compared to nondepleted recipients ( Figure 6D ).
These results indicate that reduction of Th17 cells, IL-6, and IL-17A
are associated with amelioration of some aspects of allograft injury. 
| MCMV donor/recipient infection with different strains exacerbates NK and T cell responses
| D ISCUSS I ON
In this study, MCMV recipient immune responses to infected allografts varied according to conditions of recipient primary infection. A model synthesizing these findings is shown in Figure 10 .
The most striking differences were observed among NK cells. The D+/R-primary NK response consisted of high cytolytic (IFN-γ+) and cytotoxic (GzB+) NK cells, which were lower among recipients with NK memory after high-dose primary MCMV infection (10 4 pfu).
Recipients infected with a low MCMV primary inoculum (10 2 pfu) manifested primary-like high cytolytic and cytotoxic NK responses despite prior MCMV immunity, whereas the NK memory response reported. 54 In another study, kidney transplant patients with posttransplant CMV infection had higher pretransplant plasma IL-23 levels compared to patients without posttransplant CMV infection.
60
Together, these studies support the potential significance of Th17 cells in CMV-associated allograft dysfunction and might be of particular interest given the recent availability of biological response modifiers directed against IL-23 for autoimmune diseases, which could potentially be used to dampen Th17 responses during acute rejection.
In this model, tissue injury and characteristics of allograftinfiltrating immune cells were independent of the tissue viral loads, suggesting that the host response rather than the virus itself might induce allograft injury. This is consistent with our prior work, where MCMV-associated allograft damage was reduced by NK depletion.
In addition, results from this study indicate that D/R infections with different strains increase immune-mediated graft injury, a scenario that likely has clinical relevance for HCMV D+/R+ transplants. NK KIR activating polymorphisms can confer protection from CMV infection (DNAemia), but it is unknown whether donor-derived HCMV strains can activate or inhibit NK cells according to recipient KIR polymorphisms. 16, 18, 61 There are limitations to the interpretation of this study. All experiments were conducted using a murine strain combination that acutely rejects allografts, so the impact of host strain major histocompatibility complex (MHC) differences and less-stringent infiltrates. The observations in this model require further evaluation in clinical populations, and a better understanding of these pathways might identify potential interventions to prevent or treat early CMV-associated allograft injury that may contribute to late allograft loss. 
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